CN104490915A - Antiviral pharmaceutical composition - Google Patents
Antiviral pharmaceutical composition Download PDFInfo
- Publication number
- CN104490915A CN104490915A CN201410628693.9A CN201410628693A CN104490915A CN 104490915 A CN104490915 A CN 104490915A CN 201410628693 A CN201410628693 A CN 201410628693A CN 104490915 A CN104490915 A CN 104490915A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- pharmaceutical composition
- composition
- antiviral
- hsv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention relates to an antiviral pharmaceutical composition, which takes cylindrin, dracorhodin, aucubin and solasonine as raw materials through preparation ratio, various dosage forms can be prepared according to a conventional preparation technology, and the pharmaceutical composition has important meaning for preparing the antiviral drugs.
Description
Technical field
The invention belongs to biomedicine field, relate to a kind of antiviral medicinal composition.
Background technology
At present a large amount of bacterial drug resistance using antibiotic to cause constantly rises has become one of difficult problem of jointly paying close attention in the whole world.Especially the resistant rate of staphylococcus aureus reaches more than 90%.Herpes simplex virus type II mainly causes genital area mucocutaneous infections.Virus enters body through respiratory tract, oral cavity, genital mucosa and damaged skin, dives and occupy in human normal mucosa, blood, saliva and sensory nerve ganglion cell.When Abwehrkraft des Koepers declines, as heating, gastrointestinal dysfunction, menstruation, gestation, focal infection and mood change time, the HSV-II hidden in body is activated and falls ill.The antiviral drugs that synthetic drug is comparatively affirmed in the treatment of herpes simplex is acyclovir (ACV), but the persister of clinical continuous discovery ACV in recent years, and drug resistance has growth trend with the prolongation of courses of pharmaceuticals.
Therefore, antibacterial, the antiviral drugs of developing new high-efficiency low-toxicity have broad prospects, the multiple target effect mechanism of Chinese medicine, low toxic and side effects, be easy to metabolism, the advantage such as to have no drug resistance makes it become the focus of antibacterial, the antiviral drugs of screening high-efficiency low-toxicity.
Cylindrin (cylindrin): CAS 17904-55-1, molecular formula C
31h
52o, molecular weight 440.74398.Dracorhodin (cochinchinenin): CAS 400603-95-4, molecular formula C
31h
30o
7, molecular weight 514.57.
Aucubin (aucubin): CAS 479-98-1, molecular formula C
15h
22o
9, molecular weight 346.33, aucubin is a kind of important bioactive substance, has the effects such as clearing away damp-heat, diuresis, analgesia, blood pressure lowering, hepatoprotective, antitumor.It can promote stem cell regenerating, obviously suppresses copying of hepatitis B virus DNA, and its aglycon and effectively polymer are a kind of antibiotics.It is one of effective ingredient of the Chinese crude drugs such as the Cortex Eucommiae, Herba Plantaginis, Radix Rehmanniae, is again the quality index of some patent medicine.
Solasonine (solasonine): CAS 19121-58-5, molecular formula C
45h
73nO
16, molecular weight 884.06.
4 kinds of medicines structures of pharmaceutical composition of the present invention are as follows:
Cylindrin (cylindrin) dracorhodin (cochinchinenin)
Aucubin (aucubin)
Solasonine (solasonine).
Summary of the invention
The object of the invention is the deficiency overcoming background technology, a kind of antiviral medicinal composition is provided.
The present invention is achieved through the following technical solutions:
Composition and the weight portion of the crude drug of a kind of antiviral medicinal composition of the present invention are:
Cylindrin 20-40 weight portion dracorhodin 5-20 weight portion aucubin 15-35 weight portion solasonine 1-10 weight portion.
A kind of antiviral medicinal composition of the present invention can adopt the conventional method of galenic pharmacy to be prepared into tablet, capsule, drop pill.
A kind of antiviral medicinal composition of the present invention, is characterized in that for antiviral.
Pharmaceutical composition of the present invention passes through multicomponent, too many levels, multipath ground plays synergism and show antiviral efficacy, invades to HSV-II the Main Function approach that the blocking effect of cell and direct kill virus are pharmaceutical composition extracorporeal antivirus effects of the present invention.HSV-II is tunicary virus, and outermost peplos is made up of lipid and glycoprotein, and wherein any one composition changes, and can make peplos degeneration, thus inactivation of viruses.Experimental result shows that the direct deactivation of pharmaceutical composition of the present invention to HSV-II is stronger.The blocking effect research that HSV-II invades cell shows, pharmaceutical composition of the present invention not only has antiviral activity, also has the effect that to a certain degree Cell protection prevents Virus entry.Utilize HSV-II encephalitis model to study the protective effect of pharmaceutical composition of the present invention to HSV-II infecting mouse, result shows that pharmaceutical composition of the present invention shows certain antiviral activity.
Detailed description of the invention
Below by specific experiment example and embodiment, a kind of antiviral medicinal composition of the present invention is described further, but is not limited to the present invention.
Embodiment 1: antiviral medicinal composition
The composition of the crude drug of antiviral medicinal composition and weight portion are:
Cylindrin 20 weight portion dracorhodin 20 weight portion aucubin 15 weight portion solasonine 1 weight portion
Embodiment 2: antiviral medicinal composition
The composition of the crude drug of antiviral medicinal composition and weight portion are:
Cylindrin 40 weight portion dracorhodin 5 weight portion aucubin 35 weight portion solasonine 10 weight portion
Embodiment 3: antiviral medicinal composition
The composition of the crude drug of antiviral medicinal composition and weight portion are:
Cylindrin 35 weight portion dracorhodin 15 weight portion aucubin 20 weight portion solasonine 5 weight portion
Embodiment 4: antiviral medicinal composition
The composition of the crude drug of antiviral medicinal composition and weight portion are:
Cylindrin 25 weight portion dracorhodin 18 weight portion aucubin 25 weight portion solasonine 6 weight portion
Embodiment 5: the preparation of tablet
Example 1 compositions 150g, adds starch 75g, mixing, granulates, dry, adds microcrystalline Cellulose 20g, magnesium stearate 2.5g, and mixing, is pressed into 1000, obtains present composition tablet.
Embodiment 6: the preparation of capsule
Example 2 compositions 165g, adds starch 65g, mixing, granulates, and dry, granulate, adds appropriate magnesium stearate, and mixing, obtains present composition capsule by encapsulated 1000.
Embodiment 7: the preparation of drop pill
Taking polyethylene glycol 6000 200g water-bath (80 DEG C) heating boils molten, add embodiment 3 compositions 50g, stirring, is coolant with liquid paraffin, puts in glass tubing (4*80cm), chilling temperature is 10 DEG C, drip internal-and external diameter is 7.0/2.0 (mm/mm), and drip is 2cm apart from liquid level, drips speed with per minute 50 for optimum condition, blot the condensing agent on drop pill surface with cotton, obtain present composition drop pill.
Experimental example 1: pharmaceutical composition antibacterial action
1. strain and culture medium
Experimental strain is provided by Center for Disease Control (CDC) of Shandong Province and Clinical Laboratory center, Shandong Province.Be listed as follows:
Experiment culture medium: antibacterial MH culture medium, fungus PDA culture medium is all purchased from Nat'l Pharmaceutical & Biological Products Control Institute.
2. fungistatic effect detection method:
2.1 fungistatic effects cylinder plate method measures inhibition zone size
Activation bacterium liquid physiological saline solution is diluted to 10
5~ 10
6cfu/ml is for subsequent use.Add 0.2ml bacterium liquid to dry MH culture medium flat plate, smoothen.Place 5min, make culture medium fully absorb bacterium liquid.6, sterilized Oxford cup placed by each flat board, places 5min, makes Oxford cup adsorbed close in media surface.0.1g/ml water extract 100ul is added in the cup of Oxford.Positive control levofloxacin and fluconazol.Positive control antibacterial concentration is 40 μ g/ml levofloxacin, and Candida albicans concentration is 200 μ g/ml fluconazol, all adds 100ul.Negative control adds sterilized water.Then flat board is placed in 37 DEG C of constant incubators and cultivates 24h (candida albicans 48h), go out and measure antibacterial circle diameter with slide calliper rule, calculating mean value, represent bacteriostatic activity with antibacterial circle diameter D.Fungistatic effect criterion is: D≤8mm is insensitive, and 8mm < D≤13mm is less sensitive, and 13mm < D≤19mm is medium sensitivity, and D > 19mm is extremely sensitive.
The mensuration of 2.2 minimal inhibitory concentration MIC adopts Microdilution plate method
Test bacterial concentration is 10
6cfu/ml.Drawing the bacterium liquid diluted is added in 96 porocyte culture plates, every hole 100ul, often kind of medicine 100ul, contrast dilution 10 hole successively, last hole does not add medicine (only adding culture medium and antibacterial) and adds dilution bacterium liquid 100ul, is bacterial growth control hole.Stay string hole not add antibacterial (only adding culture medium and medicine) and do drug control hole, positive control levofloxacin and fluconazol, illustratively do doubling dilution.Be placed in 1min that agitator vibrates, make after in hole, solution fully mixes, microwell plate is added a cover and is placed on and is covered with in the square enamel tray of wet gauze, in 37 DEG C of incubators, hatch 24h (candida albicans 48h), observe and be minimal inhibitory concentration without lowest concentration of drug contained by bacterial growth hole.
3. fungistatic effect
The each pharmaceutical composition inhibition zone (mm) of table 1
Note: a, embodiment 2 pharmaceutical composition, embodiment 1 pharmaceutical composition, embodiment 3 pharmaceutical composition, embodiment 4 pharmaceutical composition addition are 1mg/ cup, b, positive control antibacterial concentration are 40 μ g/ml levofloxacin, Candida albicans concentration is 200 μ g/ml fluconazol, all adds 100ul.5%DMSO is negative control.
Table 2: different pharmaceutical compositions minimal inhibitory concentration (MIC) (unit mg/ml)
Note: positive control antibacterial levofloxacin, Candida albicans fluconazol, all adds 100ul.5% DMSO is negative control.
Result shows: pharmaceutical composition of the present invention has broad-spectrum antiseptic and bactericidal action.To gram positive bacteria: staphylococcus aureus, drug resistance staphylococcus epidermidis, bacillus cereus, bacillus subtilis; Gram negative bacteria: escherichia coli, enterococcus faecalis; Deep infection fungus Candida albicans has the effect killed with Developing restraint, has important practice significance and using value, can have in the food of antibacterial and/or bactericidal action, health product, cosmetics and medicine apply in preparation.
Experimental example 2: pharmaceutical composition antivirus action
1, experiment material
Virus: HSV-II type (3 generation) 20110913, Lanzhou Institute of Biological Products's vaccine research room provides (herpessimplex virus, HSV-II)
Cell: African green monkey kidney cell (Vero cell) Lanzhou Institute of Biological Products provides.Cultivate with DMEM culture medium+7% Ox blood serum.
Animal: cleaning grade kunming mice, male and female half and half, body weight 18-22g, is purchased from Lanzhou Institute of Biological Products's Animal House.
Medicine and reagent: tetrazolium bromide (MTT, Fluka Biochemika company), dimethyl sulfoxide (dimethylsulfoxide, DMSO, Sigma company produces), DMEM (GIBCO company), standard neonatal Ox blood serum (sino-america joint-venture Lanzhou people's marine growth Engineering Co., Ltd), Aciclovir for injection (ACV, 9-(2-hydroxyl ethoxymethyl-) guanine, Wuhan Pusheng Pharmaceutical Co., Ltd., the accurate word H42020129 of product batch number 110811 traditional Chinese medicines).Embodiment 2 pharmaceutical composition, embodiment 1 pharmaceutical composition, embodiment 3 pharmaceutical composition, embodiment 4 pharmaceutical composition, be embodiment 1 method and prepare, lot number is respectively: 20110208,20110209,20110210,20110211.
2, experimental technique
2.1 experiment in vitro
2.1.1 drug cytotoxicity measures (MTT method)
By cell suspension with 8 × 10
5/ ml density is inoculated in 96 porocyte culture plates, every hole 200 μ l, 37 DEG C, 5%CO
2, 100% relative humidity cultivates 24h.Embodiment 2 pharmaceutical composition, embodiment 1 pharmaceutical composition, embodiment 3 pharmaceutical composition, the equal doubling dilution of embodiment 4 pharmaceutical composition are to following 6 concentration: 16,8,4,2,1,0.5mg/ml, add in cell suspension hole, each drug level repeats 4 holes, separately establishes normal cell controls.Continue under the same terms to cultivate 33h, observation of cell pathological changes (CPE) situation, and detect cell survival rate with MTT method.
2.1.2 virus virulence measures (plaque method)
By cell suspension with 8 × 10
5/ ml density is inoculated in 24 porocyte culture plates, every hole 1mL, 37 DEG C, 5% CO
2, 100% relative humidity cultivates 24h.Viral dilution is to following 6 concentration: 10
-3, 10
-4, 10
-5, 10
-6, 10
-7, 10
-8, add in cell suspension hole, each drug level repeats 4 holes, separately establishes normal cell controls, and methylcellulose covering covers, and continues to cultivate 72h, violet staining, counting under the same terms.
Infectious virus amount (PFU/ml)=(speckle number in every hole/every hole virus inoculation amount ml) × viral dilution multiple.
2.1.3 medicine invades the blocking effect (plaque method) of cell to HSV-II
Test sample liquid is mixed with HSV-II equal-volume, infects Vero cell with this virus drugs mixed liquor.37 DEG C, 5%CO
2absorption 90min, washing, adds cell maintenance medium and puts 37 DEG C, 5%CO
2cultivate.Every day observes CPE, detects viral suppression after 72h with plaque method.Therapeutic index (TI) is adopted to weigh the suppression effect of drug on viral as evaluation index.Therapeutic index (TI)=half toxic concentration (TC
50)/half suppresses dense (IC
50).Each drug level repeats 4 holes, arranges normal cell controls, drug control and virus control simultaneously.
2.1.4 medicine is to the direct deactivation (plaque method) of HSV-II
Test sample liquid is mixed with HSV-II equal-volume, after 37 DEG C of effect 90min, infects Vero cell with this virus drugs mixed liquor.37 DEG C, 5% CO
2absorption 90min, washing, the same method is cultivated and is checked.
2.1.5 the inhibitory action (plaque method) of drug on viral granule propagation
By virus infected cell, wash, add the test sample liquid of variable concentrations after absorption 90min, the same method is cultivated and is checked.Viral suppression (%)=(virus control group on average goes out speckle number-medicine-feeding test group and on average goes out speckle number)/virus control group on average goes out speckle number
2.2 experiment in vivo
2.2.1 medicine is to the determination of acute toxicity of mice
Cleaning grade Kunming mouse random packet, often organizes 6, male and female half and half.According to Vitro Experimental Results, select to suppress the active pharmaceutical composition preferably of HSV-II biosynthesis, with 400,500,625,800,1000,1250mg/kg dosage gastric infusion, separately establish negative control group, give isopyknic normal saline.Normal feed water inlet, Continuous Observation 10d, record dead mouse situation also calculates LD
50.
2.2.2 viral encephalocoele model toxicity test
Cleaning grade Kunming mouse random packet often organizes 10, male and female half and half.After infection site routine disinfection, through right ventricle injecting virus, viral dilution is to following 6 concentration: 10
-1, 10
-2, 10
-3, 10
-4, 10
-6, 10
-7, infective dose is every 0.05mL.Normal feed water inlet, Continuous Observation 10d, record dead mouse situation also calculates LD by Reed-Muench method
50.
2.2.3 medicine infects the protective effect of HSV-II mice to encephalocoele
Cleaning grade Kunming mouse random packet often organizes 10, male and female half and half.After infection site routine disinfection, through right ventricle injecting virus, 24h after viral infection, drug treatment.By medicine LD
501/2 ~ 1/4 as the high test dose of medicine experiment in vivo, LD
501/12 ~ 1/16 as low test dose, height 2 dosage groups established by every medicine.Without the matched group (virus control group, Normal group) of medicine, continuous gastric infusion 5d, observes animal morbidity and death condition, continuous 30d.
3, experimental result
3.1 experiment in vitro
3.1.1. drug cytotoxicity measures
Table 3 different pharmaceutical compositions is to the toxicity (unit: mg/ml) of Vero cell
| Embodiment 2 pharmaceutical composition | Embodiment 3 pharmaceutical composition | Embodiment 4 pharmaceutical composition | Embodiment 1 compositions | |
| TC 50 | 3.82 | 3.78 | 4.11 | 3.76 |
The toxic action of test sample liquid to Vero cell shows as that cell proliferation is slow, granule is more, refractivity is poor, morphologic change, part cell breakage come off.Because cell metabolic activity reduces or death, the viable count that MTT method detects reduces.
3.1.2 virus virulence measures (plaque method)
Vero cell is more responsive to HSV-II, and the Vero cell pathological changes effect CPE caused by HSV-II infects is characterized as circle contracting swelling, mutually merges formation thyrsiform or starlike, even part cell detachment, forms focus.It is 10 that plaque counting obtains HSV-II type (3 generation) 20110913 infectious virus amount (PFU/ml)
7.57pFU/ml, this HSV-II virus adopts 10
-5time every hole go out speckle number and be about 40, easily count, therefore adopt 10
-5as the viral dilution of subsequent experimental.
3.1.3 HSV-II is invaded to the blocking effect of cell
Table 4 different pharmaceutical compositions invades the blocking effect of Vero cell to HSV-II
3.1.4 to the direct killing effect of HSV-II
Table 5 different pharmaceutical compositions is to the direct deactivation of HSV-II
3.1.5 to the inhibitory action (plaque method) of HSV-II virion propagation
The inhibitory action that table 6. different pharmaceutical compositions is bred HSV-II virion
Pharmaceutical composition of the present invention passes through multicomponent, too many levels, multipath ground plays synergism and show antiviral efficacy, invades to HSV-II the Main Function approach that the blocking effect of cell and direct kill virus are pharmaceutical composition extracorporeal antivirus effects of the present invention.HSV-II is tunicary virus, and outermost peplos is made up of lipid and glycoprotein, and wherein any one composition changes, and can make peplos degeneration, thus inactivation of viruses.Experimental result shows that the direct deactivation of pharmaceutical composition of the present invention to HSV-II is stronger.The blocking effect research that HSV-II invades cell shows, pharmaceutical composition of the present invention not only has antiviral activity, also has the effect that to a certain degree Cell protection prevents Virus entry.Utilize HSV-II encephalitis model to study the protective effect of pharmaceutical composition of the present invention to HSV-II infecting mouse, result shows that pharmaceutical composition of the present invention shows certain antiviral activity.
Claims (7)
1. an antiviral medicinal composition, is characterized in that the composition of the crude drug making this pharmaceutical composition and weight portion are:
Cylindrin 20-40 weight portion dracorhodin 5-20 weight portion aucubin 15-35 weight portion solasonine 1-10 weight portion.
2. according to claim 1: a kind of antiviral medicinal composition, it is characterized in that composition and the weight portion of the crude drug making this pharmaceutical composition are:
Cylindrin 20 weight portion dracorhodin 20 weight portion aucubin 15 weight portion solasonine 1 weight portion.
3. according to claim 1: a kind of antiviral medicinal composition, it is characterized in that composition and the weight portion of the crude drug making this pharmaceutical composition are:
Cylindrin 40 weight portion dracorhodin 5 weight portion aucubin 35 weight portion solasonine 10 weight portion.
4. according to claim 1: a kind of antiviral medicinal composition, it is characterized in that composition and the weight portion of the crude drug making this pharmaceutical composition are:
Cylindrin 35 weight portion dracorhodin 15 weight portion aucubin 20 weight portion solasonine 5 weight portion.
5. according to claim 1: a kind of antiviral medicinal composition, it is characterized in that composition and the weight portion of the crude drug making this pharmaceutical composition are:
Cylindrin 25 weight portion dracorhodin 18 weight portion aucubin 25 weight portion solasonine 6 weight portion.
6. a kind of antiviral medicinal composition according to claim 1, can adopt the conventional method of galenic pharmacy to be prepared into tablet, capsule, drop pill.
7. a kind of antiviral medicinal composition according to claim 1, is characterized in that for antiviral.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410628693.9A CN104490915A (en) | 2014-11-11 | 2014-11-11 | Antiviral pharmaceutical composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410628693.9A CN104490915A (en) | 2014-11-11 | 2014-11-11 | Antiviral pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104490915A true CN104490915A (en) | 2015-04-08 |
Family
ID=52932429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410628693.9A Pending CN104490915A (en) | 2014-11-11 | 2014-11-11 | Antiviral pharmaceutical composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104490915A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101473965A (en) * | 2009-01-15 | 2009-07-08 | 西北农林科技大学 | Eucommia ulmoides seed oil soft capsule rich in glycosides and preparation method thereof |
| CN102068450A (en) * | 2010-11-17 | 2011-05-25 | 山东省科学院生物研究所 | Application of aucubin to preparation of anti-thrombosis medicament |
| CN103193858A (en) * | 2013-04-12 | 2013-07-10 | 中国海洋大学 | Synthetic method of spirosolane glycoalkaloids |
-
2014
- 2014-11-11 CN CN201410628693.9A patent/CN104490915A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101473965A (en) * | 2009-01-15 | 2009-07-08 | 西北农林科技大学 | Eucommia ulmoides seed oil soft capsule rich in glycosides and preparation method thereof |
| CN102068450A (en) * | 2010-11-17 | 2011-05-25 | 山东省科学院生物研究所 | Application of aucubin to preparation of anti-thrombosis medicament |
| CN103193858A (en) * | 2013-04-12 | 2013-07-10 | 中国海洋大学 | Synthetic method of spirosolane glycoalkaloids |
Non-Patent Citations (4)
| Title |
|---|
| 焦坤等: "白茅根研究概况", 《江苏中医药》 * |
| 王进: "白茅根的药理研究及临床新用", 《中国医药指南》 * |
| 黄？缅等: "龙血竭联合HAART在静脉吸毒感染HIV/AIDS患者中的应用研究", 《中国艾滋病性病》 * |
| 黄欣等: "应用血竭治疗老年带状疱疹及护理体会", 《西南军医》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104082353A (en) | Pure traditional Chinese medicine disinfectant and preparation method thereof | |
| CN102688332B (en) | A kind of Chinese medicine composition for the treatment of flu and preparation method thereof | |
| CN106580979B (en) | Application of the pyridine heterocycle ester type compound in the drug for preparing anti-Coxsackie virus type B3 | |
| CN101933966B (en) | Active site composition of isatis roots, as well as preparation method and application thereof | |
| CN105030757A (en) | Application of epigallocatechin gallate (EGCG) in preparing drug for resisting respiratory syncytial virus | |
| CN105078934A (en) | New application of piceatannol | |
| CN109999027A (en) | The new application of epiphysin | |
| CN111676197B (en) | Vibrio harveyi phage, phage composition and application thereof | |
| CN106309455B (en) | The purposes of Peimisine | |
| CN104510754A (en) | Antiviral pharmaceutical composition | |
| CN102219772A (en) | Cortex pseudolaricis acid complex with bioactivity and preparation method thereof | |
| CN103585225B (en) | The application of a kind of Herba of Artemisiae admsii extract in preparation antiviral drugs | |
| CN104490915A (en) | Antiviral pharmaceutical composition | |
| CN104510756A (en) | Antiviral pharmaceutical composition | |
| CN104490907A (en) | Antiviral pharmaceutical composition | |
| CN110368396A (en) | The new application of retrovir | |
| CN103585189B (en) | The application of wall tapestry extract in preparation antiviral drugs | |
| CN101167822B (en) | Tibetan medicine bongga extraction and its application in preparing antiviral medicine | |
| CN104510748A (en) | Antiviral pharmaceutical composition | |
| CN104510755A (en) | Antiviral pharmaceutical composition | |
| CN104873529A (en) | Antiviral drug composition containing nuciferine | |
| CN103610705B (en) | The application of Spiraea alpina extract in preparation antiviral drugs | |
| CN112089712B (en) | Composition and application thereof in preparation of medicine for preventing and/or treating swine diseases | |
| CN101757016A (en) | Medicine composition for treating flu and preparation method thereof | |
| CN104940185B (en) | The medical usage of formoononetin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150408 |